Projects per year
Abstract
Mycobacterium tuberculosis is still the deadliest bacterial pathogen worldwide and the increasing number of multidrug-resistant tuberculosis cases further complicates this global health issue. M. tuberculosis phosphoserine phosphatase SerB2 is a promising target for drug design. Besides being a key essential metabolic enzyme of the pathogen’s serine pathway, it appears to be involved in immune evasion mechanisms. In this work, a malachite green-based phosphatase assay has been used to screen 122 compounds from an internal chemolibrary. Trisubstituted harmine derivatives were found among the best hits that inhibited SerB2 activity. Synthesis of an original compound helped to discuss a brief structure activity relationship evaluation. Kinetics experiments showed that the most potent derivatives inhibit the phosphatase in a parabolic competitive fashion with apparent inhibition constants (Ki) values in the micromolar range. Their interaction modes with the enzyme were investigated through induced fit docking experiments, leading to results consistent with the experimental data. Cellular assays showed that the selected compounds also inhibited M. tuberculosis growth in vitro. Those promising results may provide a basis for the development of new antimycobacterial agents targeting SerB2.
| Original language | English |
|---|---|
| Article number | 415 |
| Number of pages | 17 |
| Journal | Molecules |
| Volume | 25 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 19 Jan 2020 |
Funding
Funding: EP acknowledges the Fonds de la Recherche Scientifique (F.R.S.-FNRS, Belgium) for her Research Fellow grant. RS acknowledges the funding received from THSTI and Department of Biotechnology, Govt. of India (Grant ID; BT/PR29075/BRB/10/1699/2018). TG and PC acknowledge Department of Biotechnology and Department of Science and Technology (Grant ID: EMR/2016/0002405) for their respective fellowships. Acknowledgments: The pAVA0421-serb2 plasmid was generously provided by the Seattle Structural Genomics Center for Infectious Disease (www.SSGCID.org) which is supported Federal Contract No. HHSN272201700059C from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.
| Funders | Funder number |
|---|---|
| Fonds de la Recherche Scientifique F.R.S.-FNRS | |
| THSTI | |
| National Institutes of Health | |
| U.S. Department of Health and Human Services | |
| National Institute of Allergy and Infectious Diseases | |
| Institut national de la recherche scientifique | |
| Department of Biotechnology, Ministry of Science and Technology, India | |
| Fonds de la Recherche Scientifique F.R.S.-FNRS | |
| Department of Science and Technology, Government of Kerala | EMR/2016/0002405 |
| Department of Science and Technology, Government of Kerala | |
| Department of Biotechnology, Government of West Bengal | BT/PR29075/BRB/10/1699/2018 |
| Department of Biotechnology, Government of West Bengal |
Keywords
- 2,7,9-trisubstituted harmine derivatives
- M. tuberculosis
- Phosphoserine phosphatase
- SerB2
Fingerprint
Dive into the research topics of 'Identification and Repurposing of Trisubstituted Harmine Derivatives as Novel Inhibitors of Mycobacterium tuberculosis Phosphoserine Phosphatase'. Together they form a unique fingerprint.Projects
- 2 Finished
-
Structural approach of M.tuberculosis phosphoserine phosphatase as drug target for the design of original inhibitors
Pierson, E. (PI) & Wouters, J. (Supervisor)
1/10/18 → 30/09/19
Project: Research
-
Structural and inhibition study of SerB2 (Mycobacterium tuberculosis phosphoserine phosphatase)
Haufroid, M. (Researcher) & Wouters, J. (Supervisor)
1/09/16 → 31/08/22
Project: PHD